Browsing by Ajou Author

강, 석윤(Kang, Seok Yun) Currently indexed
[School of Medicine / Graduate School of Medicine] - [Hematology-Oncology]

Author IDs

ORCID
-
WOS
-
SCOPUS
-

Showing results 1 to 20 of 102

This table browses all dspace content
Pub YearTitleAuthor(s)
2024Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study강석윤
2024Differential efficacy of tyrosine kinase inhibitors according to the types of EGFR mutations and agents in non-small cell lung cancer: a real-world study강석윤, 고영화, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁
2023Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study강석윤, 권민석, 김태환, 손상용, 신승수, 안미선, 이현우, 최용원, 최진혁, 한상욱, 허훈
2022The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study강석윤, 김세혁, 노오규, 노태훈, 신승수, 안미선, 오영택, 이현우, 최용원, 최진혁
2022Erratum: Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin강석윤, 김철호, 김태환, 신승수, 신유섭, 안미선, 오영택, 이현우, 장전엽, 최용원, 최진혁, 허재성
2022Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin강석윤, 김철호, 김태환, 신승수, 신유섭, 안미선, 오영택, 이현우, 장전엽, 최용원, 최진혁, 허재성
2022Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study강석윤, 김태환, 안미선, 이현우, 최용원, 최진혁
2022Oxaliplatin (3 months v 6 months) with 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients with Stage II/III Colon Cancer: KCSG CO09-07강석윤
2022Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data강석윤, 김태환, 신승수, 안미선, 이현우, 최용원, 최진혁
2022Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer강석윤
2021Significance of descriptive symptoms and signs and clinical parameters as predictors of neuropathic cancer pain강석윤
2021Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data강석윤, 김태환, 신승수, 안미선, 이현우, 조헌도, 최용원, 최진혁
2021Early removal of central venous catheter may not impact the in-hospital mortality in patients with acute leukemia강석윤, 김태환, 박준성, 안미선, 이현우, 정성현, 최용원, 최윤석, 최진혁
2021Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)강석윤
2021Corrigendum to ‘Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer’, [Eur J Canc 51 (2015) 482–488]강석윤
2021Implications of tamoxifen resistance in palbociclib efficacy for patients with hormone receptor-positive, her2-negative metastatic breast cancer: Subgroup analyses of kcsg-br15-10 (youngpearl)강석윤
2021Clinicopathological and Molecular Analysis of 45 Cases of Pure Mucinous Breast Cancer강석윤, 김장희, 김태규, 노진, 안미선, 임현이, 정용식, 최진혁
2021Characterizing the anticancer treatment trajectory and pattern in patients receiving chemotherapy for cancer using harmonized observational databases: Retrospective study강석윤, 박래웅
2021Phase II study of DHP107 (oral paclitaxel) in the first-line treatment of HER2-negative recurrent or metastatic breast cancer (OPTIMAL study)강석윤
2020Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)강석윤
1 2 3 4 5 6

Browse